Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 108,637	$ 103,747	$ 303,397	$ 296,623
Operating expenses:
Research and development	11,545	10,907	33,819	38,554
Selling, general and administrative	28,619	27,742	87,604	82,446
Restructuring expenses		(73)		(44)
Total operating expenses	40,164	38,576	121,423	120,956
Income from operations	68,473	65,171	181,974	175,667
Other (expense) income:
Interest expense	(1,524)	(7,841)	(6,072)	(23,199)
Interest and investment income	2,807	178	4,055	546
Gain on derivatives	151	2,164	200	1,388
Other expense, net	1,434	(5,499)	(1,817)	(21,265)
Income before income taxes	69,907	59,672	180,157	154,402
Income tax (expense) benefit	(19,590)	(3,827)	(53,959)	332,672
Net income	50,317	55,845	126,198	487,074
Comprehensive income	$ 50,317	$ 55,845	$ 126,198	$ 487,074
Net income per share - basic (in dollars per share)	$ 0.33	$ 0.34	$ 0.82	$ 3.01
Net income per share - diluted (in dollars per share)	$ 0.28	$ 0.34	$ 0.69	$ 2.97
Weighted average shares used in computing net income per share - basic (in shares)	153,066	162,742	154,713	161,892
Weighted average shares used in computing net income per share - diluted (in shares)	184,465	165,242	186,504	163,930
Collaborative arrangements revenue
Revenues:
Total revenues	$ 108,637	$ 103,747	$ 303,397	$ 295,798
Sale of active pharmaceutical ingredient
Revenues:
Total revenues				$ 825